EMPAVELI ® is a targeted C3 therapy designed to regulate excessive activation of the complement cascade, part of the body’s immune system, which can lead to the onset and progression of many serious ...
EMPAVELI (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced ...
Vision impairment remains one of the most pervasive and yet preventable global health challenges. Despite remarkable progress in diagnostic and therapeutic ...
Introduction With the acceleration of the global ageing trend, sarcopenia has become a major public health problem. Probable sarcopenia, characterised primarily by decreased muscle strength, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results